Similarly, in the study of patients with autosomal dominant polycystic kidney disease, it was also reported that patients receiving tolvaptan had an increased risk of alanine aminotransferase or aspartate aminotransferase level elevation [35]. Here, GPT is linked to autosomal dominant polycystic kidney disease.